Congratulations for this major milestone for Antag Therapeutics. It has been a pleasure working with Alexander Sparre-Ulrich, Philip Just Larsen and Jeroen Bakker to achieve this successful financing. Congratulations to Alexander Mayweg, Iyona Rajkomar, MBBS, CFA, Amit Shah and Nikita Sharma !
We are excited to announce that Antag Therapeutics has closed an €80 million Series A financing round, led by Versant Ventures with participation from existing investors Novo Holdings, Longview Ventures, and Export and Investment Fund of Denmark, as well as new investors SR One Capital Management, Dawn Biopharma, Pictet Asset Management. 🎉 This funding will accelerate the clinical development of our lead candidate, AT-7687, a novel, once-weekly subcutaneous antagonist of the Glucose-Dependent Insulinotropic Polypeptide Receptor (#GIPR), targeting obesity management. It will also fuel the expansion of our pipeline of monthly injectable therapies. Preclinical studies of AT-7687 in combination with a GLP-1 receptor agonist have demonstrated the potential to deliver industry leading weight loss alongside significant metabolic benefits. With FDA clearance of our #IND application, we are thrilled to initiate Phase I clinical trials early next year, evaluating AT-7687 as both a monotherapy and in combination with a GLP-1 receptor agonist in obese patients. A huge thank you to our investors for their trust and support in helping us take this important step forward in delivering novel #obesity treatments! Read the full press release on our website, linked in the comments below. #Biotech #GIPRAntagonist #GIP #AntagTherapeutics #Financing
